ReviewBlood research2024
Functional iron deficiency anemia in patients with cancer.
Review in Blood research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- AnemiaScore: An Investigator-Developed Rule-Based Clinical Decision-Support Framework for Cancer-Related Anemia-A Single-Center Retrospective Proof-of-Concept Concordance Study.Diagnostics (Basel, Switzerland) · 2026Article
- Treatment-related Cognitive Impairment, Neurovascular Coupling, and Iron Levels in Women with Ovarian Cancer.medRxiv : the preprint server for health sciences · 2026Article
- Management of iron deficiency anemia and the role of intravenous iron supplementation in patients undergoing cancer chemotherapy: a real-world retrospective study in Japan.International journal of clinical oncology · 2026Observational
- Effect of pH and viscosity of two different iron supplements on enamel discoloration in permanent teeth: an in vitro study.BMC oral health · 2026Article
- A prospective study of intravenous iron effectiveness on quality of life and functional outcomes in patients with cancer.Scientific reports · 2026Observational
- A predictive model integrating iron metabolism and oxidative stress biomarkers with clinicopathological factors for recurrence and metastasis in oral squamous cell carcinoma.Frontiers in oncology · 2026Article
- Systemic iron availability differentially shapes tumor and brain iron handling in a sex-dependent manner in glioblastoma.PloS one · 2026Article
- Association between T cell exhaustion and the recurrence of atrial fibrillation after cryoballoon ablation.Frontiers in immunology · 2026Article
- Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes.Blood research · 2025Review
- Return to intended oncological therapy following advanced ovarian cancer surgery: a narrative review.Anaesthesia · 2025Review
- Decoding iron deficiency in cancer: mechanisms, immune modulation, and therapeutic potential.Frontiers in nutrition · 2025Review
- Preoperative red blood cell transfusion improves treatment response and survival in patients with locally advanced esophageal cancer and iron deficiency anemia.American journal of cancer research · 2025Article
- The Impact of Iron on Cancer-Related Immune Functions in Oncology: Molecular Mechanisms and Clinical Evidence.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Anemia is frequently observed in patients with cancer owing to anticancer chemotherapy, radiation therapy, and inflammatory responses. This often leads to functional iron deficiency, characterized by adequate iron stores but impaired use of iron for red blood cell production. This condition, termed functional iron deficiency anemia (IDA), is identified by a ferritin level of 30-500 µg/dL and a transferrin saturation < 50%. Functional iron deficiency often develops with the prolonged use of erythropoiesis-stimulating agents, leading to a diminished response to anemia treatment. Although oral iron supplementation is common, intravenous iron is more effective and recommended in such cases. Recent studies have shown that ferric carboxymaltose (FCM) is effective in treating functional IDA in patients with cancer. However, because of its potential to induce asymptomatic severe phosphate deficiency, it is important to closely monitor phosphate levels in patients receiving FCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.